- Vaccination News Home
- Mission Statement
- All the News
- All the News Archive
- Sandy's Scandals Column
- Sandy's Other Writings
- Adverse Reactions
- Age of Autism Articles
- Archived Sections
- Books, vaccination related
- Calendar
- Contact
- Other Websites
- Picks of the Day Archive
- Political Action
- Privacy Statement
- RedFlags Article Archive
- State Laws
- Testimonials
- Unconventional Wisdom
- Vaccines in the Pipeline
- Videos
- Video Archive
Vaccines in the PipelineDynavax Completes Enrollment and First Immunizations in Universal Flu Vaccine Study Spray vaccine to combat meningitis Good early results for herpes vaccine DNA vaccine constructs expressing Mycobacterium tuberculosis-specific genes induce immune responses NOVAVAX Announces Issuance of Key U.S. Patent for Influenza Virus-Like Particle (VLP) Vaccines New cancer vaccines study findings have been reported by researchers at Centers for Disease Control and Prevention MabVax Therapeutics Initiates Phase II Clinical Trial of Vaccine to Prevent Recurrent Sarcoma Analysis of three plasmid systems for use in DNA Aβ42 immunization as therapy for Alzheimer's disease The potential value of Clostridium difficile vaccine: An economic computer simulation model Skin patch may end the need for flu jabs by 2015 Shot May Reverse Type 1 Diabetes (includes video) Lyme borreliosis vaccination: the facts, the challenge and the future Immunacia’s Genetic Immunity Reports Phase II Data on DermaVir, a Therapeutic Vaccine for HIV/AIDS, During the XVIII International AIDS Conference: A 70% Viral Load Reduction Demonstrated in HIV Drug-naïve Individuals PharmAthene Develops Thermostable Lyophilized rPA Anthrax Vaccine Under a Challenge Grant From the National Institutes of Health Immunization with a Combination of Integral Chlamydial Antigens and a Defined Secreted Protein Induces Robust Immunity Against Genital Chlamydial Challenge Title: Antibody fusion proteins: effective adjuvants of protein vaccination Dengue Re-emerges in U.S., Spurring Race for Vaccine Mymetics' Respiratory Syncytial Virus (RSV) Vaccine Protects From Viral Challenge in Pre-Clinical Study $1.5 million to position Queensland as international leader in the fight against Hendra Virus Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector Title: Ostertagia vaccine Researchers test lung cancer vaccine (includes video) Oral Vaccination with Attenuated Salmonella enterica Strains Encoding T-Cell Epitopes from Tumor Antigen NY-ESO-1 Induces Specific Cytotoxic T-Lymphocyte Responses Construction and analysis of an experimental Streptococcus iniae DNA vaccine 'Vaccine-in-a-bag' aims to end needle pain UK researchers start human trials on melanoma vax 'cure' Inviragen’s Dengue Vaccine to Begin Clinical Testing 'Anti-obesity vaccine' developed What's Next in Vaccines? HIV, Malaria, Rabies, MRSA, and 30 Other Vaccine Targets in the 2010-2020 New vaccines for tuberculosis Gates Foundation Researches Nanoparticle Vaccines Triggered by Sweat May 2010 - Efficacy of a Potential Trivalent Vaccine Based on Hc Fragments of Botulinum Toxins A, B, and E Produced in a Cell-Free Expression System - journal article (Clinical and Vaccine Immunology) May 5, 2010 - Inhalable Measles Vaccine Seen as Treatment Boon (includes video) - CBS News - "The process developed by a team of researchers at the University of Colorado at Boulder, basically involves taking a deep breath from the inhalable powdered vaccine - which gets sent straight into a recipient's lungs. Here's a short video explaining how the vaccine works." May 5, 2010 - New inhalable measles vaccine may lead to vaccines for other diseases - Dry powder vaccine set for clinical trials this year in India - University of Colorado at Boulder via EurekAlert! May 5, 2010 - Scancell Holdings Plc ('Scancell' or the 'Company') Clinical Trial Approval for SCIB1 melanoma vaccine study - Scancell Holdings via Business Wire via Alpha Trade May 4, 2010 - GlycoVaxyn and a Harvard University Affiliated Hospital Receive USD 3.4 Million NIH Grant for Staphylococcus aureus Vaccine Development - Program to leverage GlycoVaxyn Proprietary in vivo conjugation technology - GlycoVaxyn via Alpha Trade May 2, 2010 - New vaccines may come from forcing giardia parasite to display its many disguises - EurekAlert! via Web Newswire - "Luján reasoned that this genetically-altered parasite might make an optimal vaccine." April 30, 2010 - Advaxis’ Live Listeria Prostate Cancer Vaccine Heads for Clinic - press release - Advaxis, Incorporated via Business Wire April 30, 2010 - Doctors create first vaccine to prevent urinary tract infections (includes video) - KING 5 News April 29, 2010 - Companies explore promise of oncolytic immunity - FierceVaccines - "OncoVEX includes an oncolytic virus, a reprogrammed virus that has been converted into a cancer-fighting agent that attacks tumor cells while leaving healthy cells undamaged. When an oncolytic immunotherapy like OncoVex is injected into a patient, it replicates in tumor cells only, causing cell lysis." April 28, 2010 - Immunovo Negotiates Deal for Pepscan’s Therapeutic Vaccine Portfolio - Genetic Engineering & Biotechnology News - "The firm says partnering its vaccine candidates will allow it to concentrate its resources on the development of mAbs and therapeutic peptides using its protein mimicry technology, CLIPS™ (chemical linkage of peptides onto scaffolds)." April 28, 2010 - Data From LigoCyte's Clinical Studies of Norovirus VLP Vaccine Presented at 13th Annual Conference on Vaccine Research - Intranasal Norovirus Vaccine Demonstrates Immunogenicity in Phase I Studies - press release - LigoCyte Pharmaceuticals, Inc. via PRNewswire April 28, 2010 - Virosome-based vaccine completes safety, efficacy tests - Pevion Biotech has successfully completed preclinical safety and efficacy studies of its RSV vaccine candidate, which uses a virosome-based delivery platform. - in-PharmaTechnologist April 26, 2010 - Pevion Announces Excellent Preclinical Results for PEV4 RSV Vaccine Candidate - Previon via BusinessWire via Euro Investor, UK April 26, 2010 - ALK proposes to acquire the largest allergy vaccine company in the Netherlands - Fornix BioSciences via Euro Investor, UK April 21, 2010 - Notice: Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning a Chimeric Ebola and Marburg Virus Glycoproteins Virus Like Particle Vaccine To Protect Against Diverse Ebola and Marburg Viruses - Department of the Army, DoD via www.pharmcast.com April 24, 2010 - AFFiRiS' AD02 Alzheimer's vaccine candidate in phase II clinical testing - AFFiRiS AG via News-Medical.Net April 22, 2010 - IAVI and Lentigen to Collaborate on Design of Novel AIDS Vaccine Candidate - press release - Lentigen Corporation via PRNewswire - "Lentigen's technology relies on a synthetic version of a virus related to HIV that has been engineered, along with other safety modifications, to be incapable of inserting itself into the human genome." April 22, 2010 - Liquidia closes $25M Series C to fund vaccine delivery tech - FierceVaccines - "Liquidia, which is based in Research Triangle Park, NC, uses its PRINT technology to create nanoparticles that can be used to more precisely deliver vaccine payloads, improving the safety and efficacy of the jab." April 21, 2010 - Potent Immunity to Low Doses of Influenza Vaccine by Probabilistic Guided Micro-Targeted Skin Delivery in a Mouse Model - journal article (PLoS One) - "Here we show that the Nanopatches deliver a seasonal influenza vaccine (Fluvax® 2008) to directly contact thousands of APCs, in excellent agreement with theoretical prediction. By physically targeting vaccine directly to these cells we induced protective levels of functional antibody responses in mice and also protection against an influenza virus challenge that are comparable to the vaccine delivered intramuscularly with the needle and syringe—but with less than 1/100th of the delivered antigen." April 21, 2010 - ImmunoCellular Therapeutics Enters into Research Agreement with University of Pennsylvania to Support Phase II Clinical Trial of ICT-107 - ImmunoCellular Therapeutics via Business Wire via MarketWatch - "ICT-107 is a dendritic-cell based vaccine that works by activating a patient's immune system against specific tumor-associated antigens. This is accomplished by extracting dendritic cells from a patient, loading them with the antigens, and reintroducing them to the patient's body to trigger an immune response." April 19, 2010 - NanoBio To Develop Vaccine For Treatment Of Hepatitis B - NanoBio Corporation via Michigan Technology News - "Michigan Nanotechnology Institute for Medicine and Biological Sciences received funding through a Phase 1 Technology Transfer award by the National Institutes of Health (NIH), to evaluate a potential therapeutic intranasal vaccine for the treatment of hepatitis B in patients." April 19, 2010 - Vaccine For Urinary Tract Infections - TheDenverChannel.com April 18, 2010 - Protein Potential LLC Awarded $3 Million U.S. NIH Phase II Small Business Innovation Research Grant to Develop a Vaccine Targeting Plasmodium vivax, a Neglected Cause of Malaria - Protein Potential LLC via PRNewswire via News Blaze May 15, 2010 - \Update on Research and Development Pipeline: Tuberculosis Vaccines - journal article (Clinical Infectious Diseases) April 26, 2010 - An inactivated West Nile Virus vaccine derived from a chemically synthesized cDNA system - journal article (Vaccine) April 26, 2010 - Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types - journal article (Vaccine) April 14, 2010 - Aeras and Crucell Announce Start of Phase II TB study in South Africa - Crucell and Aeras via Marketwire via COMTEX via MarketWatch - "Dutch biopharmaceutical company Crucell N.V. /quotes/comstock/15*!crxl/quotes/nls/crxl (CRXL 20.53, +0.14, +0.69%) (SWISS: CRX) and the Aeras Global TB Vaccine Foundation today announced the start of a Phase II clinical trial of the jointly developed tuberculosis (TB) vaccine candidate AERAS-402/Crucell Ad35 in HIV infected adults. The Phase II study is designed to test the safety and efficacy of AERAS-402/Crucell Ad35 in adults infected with HIV and will be conducted by the Aurum Institute in Klerksdorp, South Africa. All Aeras-sponsored TB vaccine candidates have been or will be tested for safety in people living with HIV." April 13, 2010 - Oral Vaccine May Reduce Exacerbations in Patients With COPD - A novel vaccine may help reduce the number and severity of exacerbations in patients with severe chronic obstructive pulmonary disease (COPD). - American College of Chest Physicians via ScienceDaily April 12, 2010 - Sanofi Pasteur ties up with US NMRC to develop travelers diarrhea vax - BioSpectrum - "The core ETEC adhesin vaccine technology, developed by NMRC, was exclusively licensed to Sanofi Pasteur, along with a second technology that efficiently packages the adhesin with a toxoid vaccine component, co-developed by NMRC and the University of Colorado Denver." March 23, 2010 - Title: Generation of virus-like particles and use as panfilovirus vaccinewww.pharmcast.com Patent application title: DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES - Inventors: Jens-Peter Gregersen - Agents: NOVARTIS VACCINES AND DIAGNOSTICS INC. - Assignees: CHIRON BEHRING GMBH & CO. - www.faqs.org Novartis Vaccines And Diagnostics Inc. patents - The following is a sampling of recent Novartis Vaccines And Diagnostics Inc. patent applications (USPTO Patent Application #, Patent Title) sorted by month. - FreshPatents.com April 2010 - Enhancing DNA vaccine potency by co-administration of xenogenic MHC class-I DNA - journal article (Gene Therapy) April 2010 - Vaccination with a potent DNA vaccine targeting B-cell epitopes of hGRP induces prophylactic and therapeutic antitumor activity in vivo - journal article (Gene Therapy) April 6, 2010 - MOLOGEN AG receives funding to develop a DNA vaccine against hepatitis B - The DNA specialists from Berlin are intensifying their work on developing innovative and improved DNA-based vaccines. This is a response to a high demand - with an interesting market potential - PipelineReview.com April 2010 - Randomized Trial on the Safety, Tolerability, and Immunogenicity of MenACWY-CRM, an Investigational Quadrivalent Meningococcal Glycoconjugate Vaccine, Administered Concomitantly with a Combined Tetanus, Reduced Diphtheria, and Acellular Pertussis Vaccine in Adolescents and Young Adults - journal article (Clinical and Vaccine Immunology) April 7, 2010 - Cancer vaccines may be on the verge of wider use - Pittsburgh Post-Gazette - "The encouraging results of MUC1 vaccines aren't confined to animals. The version that is now being tested by Merck showed a 17-month survival advantage for advanced lung cancer patients who got the vaccine vs. those who didn't in an earlier trial. While the current testing has been suspended temporarily because one patient got encephalitis, the man whose company invented the vaccine is encouraged by the progress it has made. Robert Kirkman, president of Oncothyreon, the Seattle, Wash., company that developed the vaccine, said he understands the logic of testing cancer vaccines on patients who aren't as sick, but said that presents a financial challenge. If vaccines were to be tested on a large group of patients with earlier stage cancer, it could mean following them for up to 10 years to see if the therapy was effective, and that would be enormously expensive." April 7, 2010 - iBio Announces Rights Grant for Anthrax-Plague Combination Vaccine - Business Wire via MarketWatch - "iBio and CMB have developed a new biologics production platform based on the use of green plants to manufacture vaccines and therapeutic proteins. The technology has been successfully applied to a variety of candidate products, including an avian influenza vaccine planned to be the first product to enter a human clinical trial in 2010." April 6, 2010 - Oral Vaccine May Reduce Exacerbations in Patients With COPD - American College of Chest Physicians via Doctor's Guide - "Maharaj Kishore Tandon, MD, Hollywood Private Hospital, Perth, Western Australia, and colleagues developed a new oral immunotherapy (HI-164OV) using Haemophilus influenzae." April 6, 2010 - Netherlands Vaccine Institute, PharmaJet Collaborate For Needle-free Delivery - Netherlands Vaccine Institute (NVI) and PharmaJet have entered into a collaboration to evaluate PharmaJet's intra-dermal needle-free delivery technology with NVI's Salk inactivated polio vaccine (IPV). - Pharmaceutical Business Review April 6, 2010 - Crucell Announces Collaboration with GlaxoSmithKline Biologicals on Second Generation Malaria Vaccine Candidate - Crucell via Marketwire via CNN Money - "Under the terms of the letter of agreement, Crucell will contribute its recombinant malaria vaccine candidate, Ad35-CS, based on Crucell's AdVac® technology and PER.C6® manufacturing platform and GSK will contribute its late stage malaria vaccine candidate RTS,S/AS. Financial details of the agreement were not disclosed." April 1, 2010 - Notice: Prospective Grant of Exclusive License: Development of PANVAC and Tumor Associated Antigens as Cancer Vaccines - National Institutes of Health, Public Health Service, HHS via www.pharmcast.com - "The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory may be worldwide and the field of use may be use of Licensed Patent Rights for development of therapeutics for human cancers. The field of use will specifically exclude prostate cancer, melanoma and colorectal cancer. For the avoidance of doubt, delivery formulations shall specifically exclude canary poxvirus vectors, NYVAC, non-viral eukaryotic expression vectors and recombinant yeast vectors in all geographic territories." April 4, 2010 - Scientists at Gorlaeus Laboratories report research in atherosclerosis vaccines - Cardiovascular Research via NewsRx May 1, 2010 - Effect of Vaccination with Modified Vaccinia Ankara (ACAM3000) on Subsequent Challenge with Dryvax - journal article (The Journal of Infectious Diseases) * May 1, 2010 - Randomized Controlled Clinical Trial of Fractional Doses of Inactivated Poliovirus Vaccine Administered Intradermally by Needle‐Free Device in Cuba - journal article (The Journal of Infectious Diseases) (patent) - The United States of America as represented by the Secretary of the Army (Washington, DC) via * April 1, 2010 - Vaccine with no jab: Protein
vaccines for needle-free immunization through the skin - Most immunizations
currently involve an injection in the arm. In the future, vaccination may be
accomplished without the unpleasant jab of a needle: a team led by Victor C.
Yang at the University of Michigan (USA) has developed a method by which
vaccines can pass directly through the skin without a needle. As the researchers
report in the journal Angewandte Chemie, merely linking a special short peptide
molecule to the vaccine, which can then be administered in the form of
a patch, will do the job. - PhysOrg.com
April 24, 2010 - AFFiRiS' AD02 Alzheimer's vaccine candidate in phase II clinical testing - AFFiRiS AG via News-Medical.Net April 22, 2010 - IAVI and Lentigen to Collaborate on Design of Novel AIDS Vaccine Candidate - press release - Lentigen Corporation via PRNewswire - "Lentigen's technology relies on a synthetic version of a virus related to HIV that has been engineered, along with other safety modifications, to be incapable of inserting itself into the human genome." April 22, 2010 - Liquidia closes $25M Series C to fund vaccine delivery tech - FierceVaccines - "Liquidia, which is based in Research Triangle Park, NC, uses its PRINT technology to create nanoparticles that can be used to more precisely deliver vaccine payloads, improving the safety and efficacy of the jab." April 21, 2010 - Potent Immunity to Low Doses of Influenza Vaccine by Probabilistic Guided Micro-Targeted Skin Delivery in a Mouse Model - journal article (PLoS One) - "Here we show that the Nanopatches deliver a seasonal influenza vaccine (Fluvax® 2008) to directly contact thousands of APCs, in excellent agreement with theoretical prediction. By physically targeting vaccine directly to these cells we induced protective levels of functional antibody responses in mice and also protection against an influenza virus challenge that are comparable to the vaccine delivered intramuscularly with the needle and syringe—but with less than 1/100th of the delivered antigen." April 21, 2010 - ImmunoCellular Therapeutics Enters into Research Agreement with University of Pennsylvania to Support Phase II Clinical Trial of ICT-107 - ImmunoCellular Therapeutics via Business Wire via MarketWatch - "ICT-107 is a dendritic-cell based vaccine that works by activating a patient's immune system against specific tumor-associated antigens. This is accomplished by extracting dendritic cells from a patient, loading them with the antigens, and reintroducing them to the patient's body to trigger an immune response." April 19, 2010 - NanoBio To Develop Vaccine For Treatment Of Hepatitis B - NanoBio Corporation via Michigan Technology News - "Michigan Nanotechnology Institute for Medicine and Biological Sciences received funding through a Phase 1 Technology Transfer award by the National Institutes of Health (NIH), to evaluate a potential therapeutic intranasal vaccine for the treatment of hepatitis B in patients." April 19, 2010 - Vaccine For Urinary Tract Infections - TheDenverChannel.com April 18, 2010 - Protein Potential LLC Awarded $3 Million U.S. NIH Phase II Small Business Innovation Research Grant to Develop a Vaccine Targeting Plasmodium vivax, a Neglected Cause of Malaria - Protein Potential LLC via PRNewswire via News Blaze May 15, 2010 - \Update on Research and Development Pipeline: Tuberculosis Vaccines - journal article (Clinical Infectious Diseases) April 26, 2010 - An inactivated West Nile Virus vaccine derived from a chemically synthesized cDNA system - journal article (Vaccine) April 26, 2010 - Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types - journal article (Vaccine) April 14, 2010 - Aeras and Crucell Announce Start of Phase II TB study in South Africa - Crucell and Aeras via Marketwire via COMTEX via MarketWatch - "Dutch biopharmaceutical company Crucell N.V. /quotes/comstock/15*!crxl/quotes/nls/crxl (CRXL 20.53, +0.14, +0.69%) (SWISS: CRX) and the Aeras Global TB Vaccine Foundation today announced the start of a Phase II clinical trial of the jointly developed tuberculosis (TB) vaccine candidate AERAS-402/Crucell Ad35 in HIV infected adults. The Phase II study is designed to test the safety and efficacy of AERAS-402/Crucell Ad35 in adults infected with HIV and will be conducted by the Aurum Institute in Klerksdorp, South Africa. All Aeras-sponsored TB vaccine candidates have been or will be tested for safety in people living with HIV." April 13, 2010 - Oral Vaccine May Reduce Exacerbations in Patients With COPD - A novel vaccine may help reduce the number and severity of exacerbations in patients with severe chronic obstructive pulmonary disease (COPD). - American College of Chest Physicians via ScienceDaily April 12, 2010 - Sanofi Pasteur ties up with US NMRC to develop travelers diarrhea vax - BioSpectrum - "The core ETEC adhesin vaccine technology, developed by NMRC, was exclusively licensed to Sanofi Pasteur, along with a second technology that efficiently packages the adhesin with a toxoid vaccine component, co-developed by NMRC and the University of Colorado Denver." March 23, 2010 - Title: Generation of virus-like particles and use as panfilovirus vaccinewww.pharmcast.com Patent application title: DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES - Inventors: Jens-Peter Gregersen - Agents: NOVARTIS VACCINES AND DIAGNOSTICS INC. - Assignees: CHIRON BEHRING GMBH & CO. - www.faqs.org Novartis Vaccines And Diagnostics Inc. patents - The following is a sampling of recent Novartis Vaccines And Diagnostics Inc. patent applications (USPTO Patent Application #, Patent Title) sorted by month. - FreshPatents.com April 2010 - Enhancing DNA vaccine potency by co-administration of xenogenic MHC class-I DNA - journal article (Gene Therapy) April 2010 - Vaccination with a potent DNA vaccine targeting B-cell epitopes of hGRP induces prophylactic and therapeutic antitumor activity in vivo - journal article (Gene Therapy) April 6, 2010 - MOLOGEN AG receives funding to develop a DNA vaccine against hepatitis B - The DNA specialists from Berlin are intensifying their work on developing innovative and improved DNA-based vaccines. This is a response to a high demand - with an interesting market potential - PipelineReview.com April 2010 - Randomized Trial on the Safety, Tolerability, and Immunogenicity of MenACWY-CRM, an Investigational Quadrivalent Meningococcal Glycoconjugate Vaccine, Administered Concomitantly with a Combined Tetanus, Reduced Diphtheria, and Acellular Pertussis Vaccine in Adolescents and Young Adults - journal article (Clinical and Vaccine Immunology) April 7, 2010 - Cancer vaccines may be on the verge of wider use - Pittsburgh Post-Gazette - "The encouraging results of MUC1 vaccines aren't confined to animals. The version that is now being tested by Merck showed a 17-month survival advantage for advanced lung cancer patients who got the vaccine vs. those who didn't in an earlier trial. While the current testing has been suspended temporarily because one patient got encephalitis, the man whose company invented the vaccine is encouraged by the progress it has made. Robert Kirkman, president of Oncothyreon, the Seattle, Wash., company that developed the vaccine, said he understands the logic of testing cancer vaccines on patients who aren't as sick, but said that presents a financial challenge. If vaccines were to be tested on a large group of patients with earlier stage cancer, it could mean following them for up to 10 years to see if the therapy was effective, and that would be enormously expensive." April 7, 2010 - iBio Announces Rights Grant for Anthrax-Plague Combination Vaccine - Business Wire via MarketWatch - "iBio and CMB have developed a new biologics production platform based on the use of green plants to manufacture vaccines and therapeutic proteins. The technology has been successfully applied to a variety of candidate products, including an avian influenza vaccine planned to be the first product to enter a human clinical trial in 2010." April 6, 2010 - Oral Vaccine May Reduce Exacerbations in Patients With COPD - American College of Chest Physicians via Doctor's Guide - "Maharaj Kishore Tandon, MD, Hollywood Private Hospital, Perth, Western Australia, and colleagues developed a new oral immunotherapy (HI-164OV) using Haemophilus influenzae." April 6, 2010 - Netherlands Vaccine Institute, PharmaJet Collaborate For Needle-free Delivery - Netherlands Vaccine Institute (NVI) and PharmaJet have entered into a collaboration to evaluate PharmaJet's intra-dermal needle-free delivery technology with NVI's Salk inactivated polio vaccine (IPV). - Pharmaceutical Business Review April 6, 2010 - Crucell Announces Collaboration with GlaxoSmithKline Biologicals on Second Generation Malaria Vaccine Candidate - Crucell via Marketwire via CNN Money - "Under the terms of the letter of agreement, Crucell will contribute its recombinant malaria vaccine candidate, Ad35-CS, based on Crucell's AdVac® technology and PER.C6® manufacturing platform and GSK will contribute its late stage malaria vaccine candidate RTS,S/AS. Financial details of the agreement were not disclosed." April 1, 2010 - Notice: Prospective Grant of Exclusive License: Development of PANVAC and Tumor Associated Antigens as Cancer Vaccines - National Institutes of Health, Public Health Service, HHS via www.pharmcast.com - "The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory may be worldwide and the field of use may be use of Licensed Patent Rights for development of therapeutics for human cancers. The field of use will specifically exclude prostate cancer, melanoma and colorectal cancer. For the avoidance of doubt, delivery formulations shall specifically exclude canary poxvirus vectors, NYVAC, non-viral eukaryotic expression vectors and recombinant yeast vectors in all geographic territories." April 4, 2010 - Scientists at Gorlaeus Laboratories report research in atherosclerosis vaccines - Cardiovascular Research via NewsRx May 1, 2010 - Effect of Vaccination with Modified Vaccinia Ankara (ACAM3000) on Subsequent Challenge with Dryvax - journal article (The Journal of Infectious Diseases) * May 1, 2010 - Randomized Controlled Clinical Trial of Fractional Doses of Inactivated Poliovirus Vaccine Administered Intradermally by Needle‐Free Device in Cuba - journal article (The Journal of Infectious Diseases) (patent) - The United States of America as represented by the Secretary of the Army (Washington, DC) via * April 1, 2010 - Vaccine with no jab: Protein
vaccines for needle-free immunization through the skin - Most immunizations
currently involve an injection in the arm. In the future, vaccination may be
accomplished without the unpleasant jab of a needle: a team led by Victor C.
Yang at the University of Michigan (USA) has developed a method by which
vaccines can pass directly through the skin without a needle. As the researchers
report in the journal Angewandte Chemie, merely linking a special short peptide
molecule to the vaccine, which can then be administered in the form of a patch,
will do the job. - PhysOrg.com
March 29, 2010 - Immunovaccine
Begins Patient Recruitment for Phase 1 Trial of DPX-0907 Cancer Vaccine -
Marketwire via MarketWatch
linking a special short peptide
molecule to the vaccine, which can then be administered in the form of a patch,
will do the job. - PhysOrg.comMarch 29, 2010 - Immunovaccine
Begins Patient Recruitment for Phase 1 Trial of DPX-0907 Cancer Vaccine -
Marketwire via MarketWatch
April 2, 2010 - Virus 'cloaking device' explained by Oregon scientists - The Oregonian - "What they've discovered suggests that a vaccine to stop CMV may well be impossible. But the researchers believe that by re-engineering CMV, the virus could make an ideal vehicle for immunizing people against AIDS, hepatitis C, tuberculosis and other diseases that so far have defied control by conventional vaccines." April 2010 - In Situ Immunolocalization and Stage-Dependent Expression of a Secretory Serine Protease in Leishmania donovani and Its Role as a Vaccine Candidate - journal article (Clinical and Vaccine Immunology) March 2010 - New nasal spray vaccine completes phase 1 trials - Irish Medical Times April 2010 - Carbohydrate vaccines: developing sweet solutions to sticky situations? - journal article (Nature Reviews Drug Discovery) April 19, 2010 - AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice - journal article (Vaccine) April 19, 2010 - A parenteral DNA vaccine protects against pneumonic plague - journal article (Vaccine) April 19, 2010 - Novel mucosal vaccines generated by genetic conjugation of heterologous proteins to pneumolysin (PLY) from Streptococcus pneumoniae - journal article (Vaccine) April 19, 2010 - Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant - journal article (Vaccine) March 30, 2010 - Parkinson Vaccination: Good Start to the Spring for AFFiRiS AG - press release - AFFiRiS AG via PRNewswire - "Today AFFiRiS AG announced an important step forward in the development of its vaccine for Parkinson's disease. The vaccine, known as PD01, has undergone numerous preclinical tests which have confirmed its principle of action ("Proof of Concept"). The company is now starting to prepare for clinical trials of the vaccine which are planned to commence at the beginning of 2011." April 9, 2010 - A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route - journal article (Vaccine) April 1, 2010 - Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7 - journal article (Vaccine) April 1, 2010 - FDA guidance on prophylactic DNA vaccines: Analysis and recommendations - journal article (Vaccine) April 1, 2010 - Characterization of a novel live attenuated infectious bronchitis virus vaccine candidate derived from a Korean nephropathogenic strain - journal article (Vaccine) March 23, 2010 - Vaccine Therapy for Patients with Progressive Stage D0 Prostate Cancer - National Cancer Institute - "Phase I Randomized Pilot Study of Epitope-Enhanced TARP Peptide Vaccine Versus TARP Peptide-Pulsed Dendritic Cells in Patients with Biochemically Progressing Stage D0 Prostate Cancer (NCI-09-C-0139). See the protocol summary." March 16, 2010 - Title: Recombinant parainfluenza virus expression systems and vaccines (patent) - MedImmune, LLC (Gaithersburg, MD) via www.pharmcast.com March 25, 2010 - Vaccine could delay bowel inflammation and colon cancer, says Pitt research - University of Pittsburgh School of Medicine via Vidyya Medical News Service - "The researchers tested transgenic mice that spontaneously develop IBD and then progress to colitis-associated colon cancer, producing the human version of MUC1 in both disease states. They found that animals that received the vaccine showed the first signs of IBD significantly later than those in two control groups that did not get the vaccine." March 24, 2010 - Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies. (pdf) - journal article (Journal of Translation Medicine) - "As the licensed HPV vaccines target only two of the 15 high-risk HPV, one strategy is to combine many types of L1 VLPs to prevent infection against multiple high-risk types. To address this issue, a multivalent VLP vaccine is currently under clinical trial [17]. However, the inclusion of numerous VLP types complicates vaccine development and would increase the risk of antigenic competition that could result in lower protective efficacy and/or affect long lasting protection against certain HPV types." * March 22, 2010 - Pevion Biotech's PEV7 Vulvovaginal Candidiasis Vaccine Enters Phase I - Pevion Biotech, the Swiss vaccine company, today announced that PEV7, the first vaccine for chronic recurrent thrush - recurrent vulvovaginal candidiasis (VVC) has entered Phase 1 clinical trial. PEV7 aims to provide relief for an estimated 3-6 % of women worldwide who suffer from this largely unrecognized but highly debilitating condition. PEV7 has already proven to be effective in clearing the infection and preventing recurrence in animal models, and first results from the Phase I trial are expected later this year. PEV7 is based on Pevion Biotech's proprietary virosome delivery technology in which antigens bind to the surface of a "hollowed-out" virus-like particle (VLP). - press release - Pevion Biotech via Business Wire March 15, 2010 - Heat-Stable Enterotoxin of Enterotoxigenic Escherichia coli as Vaccine Target - journal article (BMC Family Practice) March 10, 2010 - Next generation of influenza vaccines may simplify storage, increase immunogenicity - Infectious Disease News March 15, 2010 - Vacc-C5 to be prepared for phase I/II clinical trial - Nutri Pharma via PR-inside.com - "Based on encouraging results from pre-clinical research, Nutri Pharma wholly owned subsidiary Bionor Immuno AS, has today announced that it will take the therapeutic and potentially preventative HIV-vaccine candidate Vacc-C5 towards phase I/II clinical trial." * March 24, 2010 - Effect of oral immunization with pooled antigens derived from adipose tissue on atherosclerosis and obesity indices - journal article (Vaccine) - "These results show that V6 is safe and holds a promise as an anti-atherogenic and overweight/obesity immune intervention." * March 24, 2010 - Oral vaccination with Ts87 DNA vaccine delivered by attenuated Salmonella typhimurium elicits a protective immune response against Trichinella spiralis larval challenge - journal article (Vaccine) March 24, 2010 - Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein - journal article (Vaccine) March 24, 2010 - Immunogenicity and efficacy of a DNA vaccine encoding a human anti-idiotype single chain antibody against nasopharyngeal carcinoma - journal article (Vaccine) * March 19, 2010 - Beta-glucan-CRM197 conjugates as candidates antifungal vaccines - journal article (Vaccine) * March 19, 2010 - Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants - journal article (Vaccine) * February 23, 2010 - Title: Intranasal vaccine for use against disease caused by enterotoxigenic Escherichia coli (patent) - Universidad Nacional Autonoma de Mexico (Mexico, MX) via www.pharmcast.com March 16, 2010 - Autologus dendritic cell vaccine for chronic hepatitis B carriers: A pilot, open label, clinical trial in human volunteers - journal article (Vaccine) March 16, 2010 - Production of H5N1 (NIBRG-14) inactivated whole virus and split virion influenza vaccines and analysis of immunogenicity in mice using different adjuvant formulations - journal article (Vaccine) March 16, 2010 - A single nasal dose of fms-like tyrosine kinase receptor-3 ligand, but not peritoneal application, enhances nontypeable Haemophilus influenzae-specific long-term mucosal immune responses in the nasopharynx - journal article (Vaccine) March 12, 2010 - Promotion of global health through oral immunotherapy using edible vaccines - Pharmainfo.net March 11, 2010 - Baxter Presents Clinical Efficacy Results from Phase III Study of Seasonal Flu Vaccine - PREFLUCEL Influenza Vaccine shows 78 percent rate of prevention against matching influenza strains - press release - Baxter International Inc. via Business Wire - "'We are pleased that these data suggest PREFLUCEL elicits a strong immune response and may prevent influenza disease in vaccinated individuals,' said Hartmut J. Ehrlich, M.D., vice president of Global Research and Development for Baxter's BioScience business. 'This is a landmark study assessing the efficacy of a cell culture-based, non-adjuvanted and preservative-free vaccine in the prevention of seasonal influenza.'" March 11, 2010 - BioSante: Positive leukemia vaccine results (requires registration) - BioSante via Chicago Breaking Business News March 2010 - Oral immunotherapy effective in fighting TB (pdf) - press release - Future Science Group - "The most promising of such approaches has been to use heat-killed suspensions of the Mycobacterium vaccae combined with chemotherapy. Repeated doses of M. vaccae are safe and very effective, but a major problem is to move from an injectable form to an oral form in order to prevent the multiple use of syringes in areas with a high incidence of HIV and tuberculosis infection." April 2010 - Impact of timing strategy of LIGHT, a new TNF superfamily on immune platform induced by HSV-1 gB DNA vaccine - journal article (Cytokine) March 2010 - Towards a vaccine against Escherichia coli-associated urinary tract infections - journal article (Future Microbiology) March 2010 - Dendritic cell-based vaccines for the therapy of experimental tumors - journal article (Immunotherapy) February 2010 - Optimised electroporation mediated DNA vaccination for treatment of prostate cancer. (free full text) - journal article (Genetic Vaccines and Therapy) Current Studies - Canadian Center for Vaccinology - "Maternal Immunization Study - Immunization of women with Diphtheria and Tetanus Toxoids combined with Acellular Pertussis (Tdap) during the mid third trimester of pregnancy: an evaluation of the potential for immunological protection for the neonate. Advertisement [pdf] Information and Authorization Form [pdf]" March 2, 2010 - Dendritic cell targeted HIV gag protein vaccine provides help to a DNA vaccine including mobilization of protective CD8+ T cells - journal article (Proceedings of the National Academy of Sciences) March 11, 2010 - Influence of serogroup B meningococcal vaccine antigens on growth and survival of the meningococcus in vitro and in ex vivo and in vivo models of infection - journal article (Vaccine) March 11, 2010 - A lyophilized formulation of RiVax, a recombinant ricin subunit vaccine, retains immunogenicity - journal article (Vaccine) March 11, 2010 - Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine - journal article (Vaccine) March 4, 2010 - BioVex Initiates Phase 1 Clinical Trial with Its Genital Herpes Vaccine, ImmunoVEXHSV2 - BioVex Inc via Business Wire via Earth Times - "ImmunoVEXHSV2 is based on a proprietary engineered form of the causative agent of genital herpes, HSV-2, from which genes that collectively interfere with the functions of immune system have been deleted. The proteins encoded by these genes aid wild type HSV-2 in evading the body’s immune system. ImmunoVEXHSV2 expresses all but four of the approximately 80 HSV-2 proteins, maximizing the breadth of the anti-HSV immune response generated, but without the genes encoding for these immune-inhibiting proteins." March 4, 2010 - 'Painless' vaccine needle invented in Japan - The fear of a visit to the doctor for an injection will soon be a thing of the past thanks to a painless new vaccine delivery system that has been perfected in Japan. - The Telegraph, UK March 4, 2010 - Possible vaccine for mesothelioma proven safe - American Thoracic Society via EurekAlert! March 4, 2010 - Groundbreaking research to find vaccine for hepatitis C - The Peninsula College of Medicine and Dentistry via PhysOrg.com March 2, 2010 - AmpVacs a Broadly Protective Synthetic Influenza A Vaccine - Sanquin Blood Supply Foundation via PRNewswire via WRIC Richmond - "Based on this notion and the proven protective effect of cytotoxic T cells on influenza A infection in preclinical models, the AmpVacs Vaccine consortium will develop an innovative fully synthetic influenza A vaccine component. To achieve this aim, the consortium will build on in-house technologies developed by the partners. Specifically, the consortium will make use of T cell imaging technology developed by one of the partners for the generation of a database of T cell epitopes. This database will then be utilized for the development and evaluation of a fully synthetic influenza A vaccine component, using specific formulation technology of the partners." March 1, 2010 - Immunization with VAR2CSA-DBL5 recombinant protein elicits broadly cross-reactive antibodies to placental-type Plasmodium falciparum infected erythrocytes - journal article (Infection and Immunity) March 2010 - Improvement of dendritic-based vaccine efficacy against hepatitis B virus–related hepatocellular carcinoma by two tumor-associated antigen gene–infected dendritic cells - journal article (Human Immunology) March 2, 2010 - AmpVacs a Broadly Protective Synthetic Influenza A Vaccine - press release - Sanquin Blood Supply Foundation via PRNewswire March 2, 2010 - ‘A pathway’ to fight Parkinson’s - Journal of Immunology via Omaha World-Herald - "A vaccine developed by UNMC researchers reverses an experimental form of Parkinson’s disease in mice." March 2, 2010 - Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults - journal article (Vaccine) - "All related systemic reactogenicity was grade 1 or 2, except one instance of grade 3 malaise. Anti-AMA1-C1 antibody responses were dose dependent and seen following each vaccination, with mean antibody levels 2–3 fold higher in the 20 μg group compared to the 5 μg group at most time points. In vitro growth-inhibitory activity was a function of the anti-AMA1 antibody titer. AMA1-C1 formulated in ISA 720 is immunogenic in malaria-naïve Australian adults. It is reasonably tolerated, though some transient, severe, and late local reactions are seen." March 1, 2010 - Maternal allergen immunisation to prevent sensitisation in offspring: Th2-polarising adjuvants are more efficient than a Th1-polarising adjuvant in mice (pdf) - journal article (BMC Immunology) March 2010 - High hopes for oral cholera vaccine - A trial of a new oral cholera vaccine in Kolkata is promising but, as Patralekha Chatterjee reports, a vaccine is only one weapon in the battle against the disease. - WHO Bulletin - "The international drive to make cholera vaccines more widely available began with Diseases of the Most Impoverished programme and the Cholera Vaccine Initiative, both funded by the Bill & Melinda Gates Foundation and coordinated by the International Vaccine Institute." February 9, 2010 - Title: Chlamydia antigens and protein vaccine (patent) - Sanofi Pasteur Limited (Toronto, Ontario, CA) via www.pharmcast.com February 25, 2010 - Dynavax picks universal flu vaccine candidate - San Francisco Business Times - "Novartis Vaccines and Diagnostics Inc. has a worldwide supply and option agreement with Dynavax for the universal flu vaccine program. Novartis’ vaccine efforts are based in Cambridge, Mass., while the Swiss company’s diagnostics unit calls Emeryville home." January 27, 2010 - Delivery of foreign antigens by engineered outer membrane vesicle vaccines - journal article (Proceedings of the National Academy of Sciences) December 15, 2009 - Modified Vaccination Technique for Prophylactic and Therapeutic Applications to Combat Endogenous Antigen–Induced Disorders - journal article (Scandinavian Journal of Immunology) December 15, 2009 - Striking Activation of NALT and Nasal Passages Lymphocytes Induced by Intranasal Immunization with Cry1Ac protoxin - journal article (Scandinavian Journal of Immunology) February 23, 2010 - GlycoVaxyn's First Clinical Study With Bioconjugate Vaccine Initiated - GlycoVaxyn via Medical News Today - "GlycoVaxyn, a pioneer in the development of innovative bioconjugate vaccines, has commenced a Phase I clinical study with its vaccine candidate (GVXN SD133) against Shigella dysenteriae, a cause of serious intestinal infections. This is the first product from the company to enter clinical evaluation." February 23, 2010 - Sanaria Inc. Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research Grant to Develop a Genetically Attenuated Whole Parasite Malaria Vaccine - Sanaria Inc. via WRIC Richmond - "The three-year award totaling approximately $3 million will support collaborative research by investigators at Sanaria and Columbia University. This new funding extends previous NIAID supported efforts at Sanaria and Columbia to develop genetically modified strains of the human malaria parasite Plasmodium falciparum that are unable to cause disease, yet stimulate protective immunity when administered as a live, whole parasite malaria vaccine." February 22, 2010 - CEL-SCI Study Shows CEL-2000 Vaccine Blocks Progression of Rheumatoid Arthritis - Statistically Significant Findings Published in Prestigious Journal of International Immunopharmacology - press release - PRNewswire-FirstCall March 1, 2010 - A Novel HLA (HLA-A*0201) Transgenic Rabbit Model for Preclinical Evaluation of Human CD8+ T Cell Epitope-Based Vaccines against Ocular Herpes - journal article (The Journal of Immunology) March 2010 - Evaluation of recombinant Brachyspira pilosicoli oligopeptide-binding proteins as vaccine candidates in a mouse model of intestinal spirochaetosis - journal article (Journal of Medical Microbiology) February 2, 2010 - Title: Malaria vaccines (patent) - Seattle Biomedical Research Institute (Seattle, WA) The United States of America as represented by the Army (Washington, DC) via www.pharmcast.com February 2, 2010 - Title: Vaccine for activating helper function of CD8.sup.+ Tcells (patent) - University of Pittsburgh - Of the Commonwealth of Higher Education (Pittsburgh, PA) via www.pharmcast.com February 19, 2010 - NOVAVAX Presents Positive Clinical Results at The World Health Organization Conference, Geneva, Switzerland - Positive Clinical Results from Pivotal Study of H1N1 Virus-Like Particle (VLP) Pandemic Influenza Vaccine in Mexico - Immunogenicity responses at all dose levels meet U.S. and European regulatory authorities recommended criteria for seroconversion and seroprotection - More than fifty percent of the volunteers already enrolled in Stage B of study - NOVAVAX via PRNewswire-FirstCall February 19, 2010 - BioCrossroads' Indiana Seed Fund Invests in Vaccine Biotech Company - BioCrossroads via PRNewswire-FirstCall - "Cook's ECM technology represents a breakthrough for tissue regeneration. Through continued research, Cook Biotech discovered a special formulation of the ECM technology can be used for other life-saving purposes, such as whole cell vaccines," said David Johnson, President and CEO of BioCrossroads. "Bioscience Vaccines is capturing those opportunities and is off to an impressive start – with real promise as a novel biotech company featuring an outstanding research team, a seasoned leadership team and a strong partnership with the University of Notre Dame." Bioscience Vaccines, Inc. has data showing that, when used as a vaccine additive (adjuvant), ECM can boost the potency of tetanus vaccine by 10 to 15 times in laboratory models." February 19, 2010 - GenVec Announces Contract With The Department of Homeland Security - GenVec via PRNewswire-FirstCall - "Under this contract, GenVec will use its adenovector technology to develop additional FMD-serotype candidate vaccines. GenVec will also explore methods to increase the potency and simplify the production process of FMD vaccines developed under this contract as well as its previous contract with the DHS announced in 2007. "This contract expands our ongoing efforts to develop adenovector-based FMD vaccines," said Dr. Paul Fischer, GenVec's President and Chief Executive Officer. "This new contract with the DHS will support new vaccine discovery and technology improvement for this important threat." February 18, 2010 - U.S. company Virxsys says using AIDS to fight AIDS - A company using genetically engineered versions of the AIDS virus says its unusual approach is getting some results, both for treating and perhaps as a vaccine against the virus. - Reuters - "Maryland-based Virxsys Corp said tests on monkeys showed its HIV-based vaccine might at least treat infections, if not prevent them, and it is now seeking permission to try it in people." February 18, 2010 - AltraVax, Inc. Acquires Revolutionary Technology Platform for Vaccine Development - DNA Shuffling Offers Potential of Rapid Vaccine Development, Broader Protection - Business Wire via MarketWatch - "The proprietary MolecularBreeding(TM) technology is part of a broader technology platform of directed molecular evolution that can be applied to the development of new and improved vaccines." February 17, 2010 - Long-Term Thermostabilization of Live Poxviral and Adenoviral Vaccine Vectors at Supraphysiological Temperatures in Carbohydrate Glass - journal article (Science) February 17, 2010 - CANFAR unveils a new HIV vaccine candidate - Canadian Foundation for AIDS Research (CANFAR) via BayToday.ca February 17, 2010 - Novartis VC arm backs universal flu shot company - * Immune Targeting Systems raises $13.6 mln in venture cash * Starting vaccine clinical trials in 2010 - Immune Targeting Systems via Reuters - "Developing a universal flu vaccine to protect people against all flu strains by targeting elements of the virus that do not change from season to season is a "holy grail" of researchers." February 17, 2010 - Scientists at German Cancer Research Center report research in human papillomavirus vaccines - German Cancer Research Center via NewsRx February 16, 2010 - Dynavax Receives Canadian Approval to Conduct Phase 3 Trials of HEPLISAV(TM) - Dynavax Technologies via Market Wire via Street Insider - "One trial is designed to demonstrate the lot-to-lot consistency of commercial vaccine and to complete the safety database for HEPLISAV, the Company's investigational adult hepatitis B vaccine. The second trial compares HEPLISAV to Engerix-B in patients with chronic kidney disease. These studies are directed toward fulfilling licensure requirements in Canada, in addition to the U.S and Europe. HEPLISAV has been shown in two previous Phase 3 trials to enhance protection more rapidly and with fewer doses than a currently licensed vaccine." February 15, 2010 - Clinical Trial Looks To Harness Body’s Own Immune System To Tackle Pancreatic Cancer - The Cancer Institute of New Jersey (CINJ) via NJToday.com - “Traditionally, vaccination treatment is always administered away from the affected site. In recent years, technology has advanced far enough to allow us to explore the option of injecting the tumor directly,” said Dr. Ben-Menachem. “It is my hope and that of the investigative team here at CINJ that we will be able to compile enough data to bring us to the next level of research. It is only through such study that we will be able to learn more about the process and improve the treatment of pancreatic cancer.” February 17, 2010 - Melbourne couples taking part in trials of male contraceptive jab - Melbourne couples are taking part in trials of a male contraceptive jab believed to be as effective as the Pill. - Herald Sun February 16, 2010 - MERIAL Receives Full License Approval for ONCEPT(TM) Canine Melanoma Vaccine - ONCEPT is the First and Only USDA-Approved, Therapeutic Vaccine for the Treatment of Cancer - press release - Merial via PRNewswire March 2010 - An HDAC inhibitor enhances the antitumor activity of a CMV promoter-driven DNA vaccine - journal article (Cancer Gene Therapy) March 2010 - Combined Administration with DNA Encoding Vesicular Stomatitis Virus G Protein Enhances DNA Vaccine Potency - journal article (Journal of Virology) February 12, 2010 - Circassia Achieves Positive Phase II Clinical Results With Ragweed Allergy T-Cell Vaccine - Results Mark Third Successful Phase II Study With ToleroMune(R) T-Cell Vaccines - PRNewswire via iStockAnalyst.com February 17, 2010 - Exposure to MF59-adjuvanted influenza vaccines during pregnancy—A retrospective analysis - journal article (Vaccine) February 17, 2010 - Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: Preliminary report of an observer-blind, randomised trial - journal article (Vaccine) February 17, 2010 - Oral immunization with a novel lipid-based adjuvant protects against genital Chlamydia infection - journal article (Vaccine) February 13, 2010 - Circassia Achieves Positive Phase II Clinical Results With Ragweed Allergy T-Cell Vaccine - Circassia via Medical News Today February 13, 2010 - Cytomegalovirus - The Centers for Disease Control and Prevention via WSOC Charlotte - "Researchers are testing a vaccine to reduce the incidence of congenital CMV infection. Study participants are girls 12 to 17. Kathryn Edwards, M.D., Vaccine Specialist at Vanderbilt University Medical Center in Nashville, says it’s important to target females before they become sexually active, so their bodies develop some immunity before pregnancy." February 13, 2010 - Inovio Reports Interim Data From Therapeutic Cervical Cancer Vaccine Trial - Inovio via Close-Up Media via COMTEX via smart-grid.tmcnet.com - "In a release, the Company noted the VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18 and is delivered via in vivo electroporation." February 11, 2010 - gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females - Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) www.clinicaltrials.gov February 9, 2010 - Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand - journal article (Immunology and Cell Biology) March 1, 2010 - Prevention of Meningococcal Disease: Current Use of Polysaccharide and Conjugate Vaccines - journal article (Clinical Infectious Diseases) - "Efforts to prevent IMD remain challenging, because there is neither an immunogenic vaccine for infants nor a vaccine to prevent serogroup B disease that is currently licensed. Obstacles to achieving optimal vaccine coverage among adolescents persist, and strategies are needed to address these shortcomings." March 1, 2010 - Epidemiological Profile of Meningococcal Disease in the United States - journal article (Clinical Infectious Diseases) - "A comprehensive program to prevent invasive meningococcal disease in the United States will require vaccination of infants; several conjugate vaccines for infants may become available in the near future. Broadly protective vaccines for endemic serogroup B disease are also needed." February 10, 2010 - Review of Biomedical Defenses to Speed Drug Development - Homeland Security Today - "PharmAthene has been producing a second- and third-generation anthrax vaccine, known as SparVax, to protect the US population against an anthrax attack by terrorists. It involves fewer doses, provides greater safety, and costs about a third compared to the current vaccine, explained Eric Richman, PharmAthene senior vice president for business development. The National Institutes of Health (NIH), which is responsible for funding early development of medical countermeasures, funded the development of SparVax originally in 2001. The US government to date has invested about $120 million in the vaccine and now receives its funding as an advanced development program from BARDA. HHS could move faster to fund the remaining development and procurement of the vaccine, Richmand told HSToday.us." February 8, 2010 - Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents - New study will focus on identification of novel B-cell epitopes on Lassa virus proteins that could result in novel agents to treat and prevent the disease - Corgenix via PRNewswire-FirstCall via WRIC.com February 9, 2010 - Vaccine firm secures £2m funding - A Scottish life science firm has secured a further £2m of funding to develop new vaccines. - BBC - "The company, Big DNA, said Scottish Enterprise had matched £1m already pledged from private investment from Hong Kong and the Channel Islands. The new £2m will be used to develop clinical trials of its Hepatitis B vaccine." February 8, 2010 - GeoVax Labs, Inc. Begins Enrollment at Final Site for Preventative Vaccine; Next Step Is to Submit IND Application for Therapeutic Vaccine to FDA - Hires Clinical Research Organization - press release - GeoVax Labs, Inc. via PRNewswire-FirstCall - "GeoVax's unique two component vaccine, a recombinant DNA and a recombinant modified vaccinia Ankara (MVA), is designed to stimulate both anti-HIV T cell and anti-HIV antibody immune responses." February 8, 2010 - Immunovaccine Presents Results for an Enhanced Anthrax Vaccine Candidate - press release - Immunovaccine Inc. via Marketwire via MarketWatch - "DepoVax is a vaccine delivery platform that uses liposomes to bring active vaccine components - antigens and immune enhancers - into an oil depot. This patented formulation creates a long lasting 'depot effect' that produces a potent humoral and/or cellular immunity, often with a single dose." February 8, 2010 - Inovio Biomedical Cervical Cancer Therapeutic Vaccine Generates Dose-Related Immune Response in Clinical Trial - Inovio via BusinessWire via Technology Marketing Corporation - "VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18 and is delivered via in vivo electroporation. Similar to previously reported data from the initial lowest dose cohort of this phase I trial, the vaccine was found to be generally safe and well tolerated. While previously reported data showed significant cellular and humoral immune responses, data from this second, intermediate dose group highlighted a significantly increased and dose-related immune response specific to the antigens targeted by the vaccine."..."While recent HPV preventive vaccines have been successful in protecting against infections that may lead to cervical cancer, Inovio's therapeutic vaccine targets the millions of women already infected with HPV and is intended to treat pre-cancerous cells and cervical cancer caused by this virus. Current vaccines do not serve this group of women," Dr. Kim added." February 10, 2010 - Development of a novel viral DNA vaccine against human papillomavirus: AcHERV-HP16L1 - journal article (Vaccine) February 10, 2010 - DNA vaccine against human papillomavirus type 16: Modifications of the E6 oncogene - journal article (Vaccine) February 10, 2010 - Novel Chlamydia pneumoniae vaccine candidates confirmed by Th1-enhanced genetic immunization - journal article (Vaccine) February 6, 2010 - Whats Next in Vaccines? HIV, Malaria, Rabies, MRSA, and 30 Other Vaccine Targets in the 2010-2020 Pipeline - Bharatbook.com added a new report on "Whats Next in Vaccines? HIV, Malaria, Rabies, MRSA, and 30 Other Vaccine Targets in the 2010-2020 Pipeline" which gives development in Vaccines market. - Bharat Book Bureau via PR Minds February 6, 2010 - Market Report, "Novavax, Inc. - SWOT Analysis", published - Datamonitor via PR-inside.com - "Novavax is a clinical stage biopharmaceutical company focused on the development of vaccines against infectious diseases, including H5N1, using proprietary virus-like particle (VLP) technology." February 6, 2010 - New Malaria Vaccine Is Safe and Protective in Children, Scientists Find - A new vaccine to prevent the deadly malaria infection has shown promise to protect the most vulnerable patients -- young children -- against the disease, according to an international team of researchers led by the University of Maryland School of Medicine's Center for Vaccine Development (CVD) and the Malaria Research and Training Center at the University of Bamako in Mali, West Africa. - University of Maryland Medical Center, via EurekAlert!, a service of AAAS via ScienceDaily February 5, 2010 - Vaccine to Protect Pregnant Women from Contracting Malaria? - Researchers at the University of Copenhagen have become the first in the world to synthesize the entire protein that is responsible for life-threatening malaria in pregnant women and their unborn children. The protein known as VAR2CSA enables malaria parasites to accumulate in the placenta and can therefore potentially be used as the main component in a vaccine to trigger antibodies that protect pregnant women against malaria. The research team is now planning to test the efficacy of the protein-based vaccine on humans. - University of Copenhagen. vua ScienceDaily February 5, 2010 - Prostate cancer vaccine progress - Irish Times - "Researchers in Cork have developed a vaccine that enables a person’s immune system to attack cancer cells directly. The scientists are now in discussions with clinicians to bring the vaccine to human trials. The vaccine is for use against prostate cancer and was developed at the Cork Cancer Research Centre at University College Cork. The vaccine is based on using DNA to stimulate the immune system and make it attack any cancer cells left after conventional surgical treatments." January 19, 2010 - Title: West nile DNA vaccine (patent) - Wyeth LLC (Madison, NJ) via www.pharmcast.com January 19, 2010 - Title: Allergy vaccine composition, production method thereof and use of same in allergy treatment (patent) - Habana, CU via www.pharmcast.com - "The vaccine composition consists of proteoliposomes derived from Gram-negative bacteria coupled to allergens and optionally contains other adjuvants or antigens. The method for its preparation and an immunization scheme of two doses are provided." February 1, 2010 - PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine - press release - PharmAthene, Inc. via PRNewswire-FirstCall February 2, 2010 - Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin - Preclinical data demonstrate the potential for long-term stability of RiVax(TM) - Soligenix, Inc. via PRNewswire-FirstCall February 2, 2010 - Salmonellosis Therapy Data on salmonellosis therapy detailed by researchers at University of Texas Medical Branch, Sealy Center for Vaccine Development - Cancer Gene Therapy via NewsRx February 2, 2010 - Scancell Holdings PLC - CTA for SCIB1 melanoma vaccine (free preview) - Scancell Holdings Plc via PR Newswire via Therapeutics Daily January 29, 2010 - Approval of Diamyd's Diabetes Vaccine Set for 2011 - HULIQ January 28, 2010 - New Vaccine Strategy May Protect Against Respiratory Syncytial Virus - A new vaccine strategy inducing antibodies capable of blocking interaction among disease-causing proteins may offer a safe and effective approach against respiratory syncytial virus (RSV). - American Society for Microbiology, via EurekAlert!, a service of AAAS via ScienceDaily January 29, 2010 - Virus-like particle vaccine could offer protection against chikungunya virus - NIH via Nature Medicine via TopNews January 28, 2010 - Vical Completes Enrollment in Allovectin-7(r) Phase 3 Trial for Metastatic Melanoma - Vical via Globe Newswire via Alpha Trade - "Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor." January 26, 2010 - 2-Pronged Immune Response Offers Hope For Effective Salmonella Vaccine - Wellcome Trust via Biocompare January 2010 - this page was not updated from June 09-Jan 2010, please search the site if you don't find what you're looking for on this page June 1, 2009 - New mothers in life-saving study - Expectant mothers booking into a Surrey maternity unit are to be asked to take part in a study aimed at creating a vaccine which could save babies' lives. - BBC - "Group B Steptococcus (GBS) affects 700 babies a year in the UK and is carried by about one in four women. ... It poses no danger to mothers but is the most common cause of life-threatening infection in newborns. It is expected to take scientists about 10 years from the end of the study to create a vaccine. The jab would be given to girls in their early teens to protect them and their babies from GBS infection in the future." April 22, 2009 - High Blood Pressure Vaccine Within Reach - The Chosun Ilbo - "But many problems need to solve before the vaccine is put to practical use. 'Patients who take high blood pressure medicine can stop taking the medicine temporarily when their blood pressure goes down due to a sudden rise in temperature,' said Lee Sang-hak, a professor of circulatory medicine at Severance Hospital. 'But after the vaccination, they can't raise their blood pressure for five or six months even if they want to, so in that case there is the risk of going into shock or becoming dehydrated due to low blood pressure.'" April 13, 2009 - Scientists to trial world first coeliac vaccine - New research could spell an end to gluten-free diets for patients with coeliac disease. (includes video) - www.abc.net.au April 5, 2009 - Stage III trials of glaucoma vaccine begins - Times of India - "The glaucoma vaccine, with the trade name Copaxone, is currently being used for patients with multiple sclerosis to reduce immune attacks on nerve cell. This vaccine, if successful in the third phase trials, will be used modify the immune mechanism." April 5, 2009 - Ebola scientists eager to be vaccinated, hope vaccine use spurs production - Canadian Press via Winnipeg Free Press March 21, 2009 - Coeliac vaccine trials world first - Australian researchers are attempting to create a new treatment for coeliac disease, writes Margaret Pincus - The Australian - "Anderson refers to the vaccine as a 'next-generation desensitisation therapy'. The treatment has been successful in mice and is now ready to be tested on humans. ... The therapy involves repeatedly injecting solutions of gluten at increasing concentrations. The aim is to desensitise the subjects slowly, in a similar way to hay fever and dust allergy desensitisation treatments." March 18, 2009 - Experimental vaccine shows promise in preventing cytomegalovirus infection - NIH/National Institute of Allergy and Infectious Diseases via EurekAlert! - "The trial evaluated an experimental vaccine made from a single CMV protein, glycoprotein B, which is known to provoke an immune response. The candidate vaccine, supplied by sanofi pasteur (Lyon, France), included an experimental adjuvant, MF59. An adjuvant is a substance added to a vaccine to improve the immune system response it elicits." March 5, 2009 - Vaccine that could prevent childhood diabetes developed by British scientists - Daily Mail, UK February 25, 2009 - Hawaii Biotech ends 1st West Nile test - Pacific Business News (Honolulu) - "Because there is no vaccine for preventing West Nile disease, Hawaii Biotech hopes to be one of the first biotech firms to get a vaccination to market for the disease, which has caused more than 1,000 deaths since it was discovered in the United States in 1999. The privately held biopharmaceutical company was founded in 1982 by nine University of Hawaii professors." November 20, 2008 - Vaccine hope in MS link to virus - Sydney Morning Herald November 16, 2008 - Skin cancer vaccine breakthrough - The pioneering Australian scientist who discovered the cure for cervical cancer is on the verge of creating the world's first vaccine for skin cancer. - The Daily Telegraph via www.news.com.au - "As with the jab now given to millions of young girls each year to prevent cervical cancer, children aged between 10 and 12 would be given the vaccine to prevent skin cancer later in life, Professor Frazer envisages. Testing on animals has shown the vaccine to be successful and human trials will start next year." October 30, 2008 - Bayhill Therapeutics and the Juvenile Diabetes Research Foundation Announce Research Collaboration for the Clinical Development of a Novel Immunotherapeutic DNA Vaccine for Type 1 Diabetes - Bayhill Therapeutics via Business Wire via MarketWatch - "BHT-3021 is an antigen-specific immunotherapeutic DNA vaccine designed to reverse the underlying autoimmune disease process in diabetes, and slow down or halt further loss of pancreatic beta cell function." October 22, 2008 - 'Flying syringe' mosquitos, other ideas get Gates funding - The Bill and Melinda Gates Foundation awarded 100,000 dollars each on Wednesday to scientists in 22 countries including funding for a Japanese proposal to turn mosquitos into "flying syringes" delivering vaccines. - AFP via PhysOrg.com August 25, 2008 - Vaccine cures dangerous yeast infections in mice - Reuters August 25, 2008 - Yeast Infection Vaccine in the Works - Researchers Report Success in Early Lab Tests for Candida Vaccine - WebMD August 21, 2008 - BioVex Announces Regulatory Clearance To Commence A Clinical Study With ImmunoVEX HSV2; A Vaccine Candidate For Genital Herpes - Medical News Today August 14, 2008 - On the way, a jab that could mean an end to arthritis - Daily Mail, UK - "The jab works by ' reprogramming' white blood cells to stop patients' immune systems attacking their own body. There are worries that it would need to be 'customised' to each patient - potentially pushing up the price to £25,000 a dose." August 13, 2008 - One injection 'vaccine' cure for arthritis within five years - A single injection that could cure rheumatoid arthritis is being developed by British scientists. - The Telegraph, UK - "Using chemicals, steroids and Vitamin D, the team has devised a way to manipulate a patient's white blood cells so they surpress, rather than activate, the immune system. It is thought the cells will then act as a brake on the over-reacting immune system and stop it attacking its own joints." January 6, 2008 - Breast Cancer Jab Could Save Many Lives - A vaccine against breast cancer is expected to be available within 10 years, a leading specialist revealed last night. - Sunday Express, UK - "'I have a vision that my grandchildren will not have the threat of breast cancer hanging over them like the sword of Damocles as women of today have,' said Dr Leathem. 'A vaccine will be the first in a new generation of treatments which will stimulate the body’s own immune system against cell structures to prevent breast cancer occurring in the first place.' His work is supported by Against Breast Cancer’s patron, Simon Cowell, whose mother Julie was cleared of the disease 10 years ago. She described the prospect of a breakthrough as 'fantastic' and added: 'One day I will take my nine-year-old granddaughter to get her vaccination against breast cancer.'" December 21, 2007 - Research Ongoing Into Preemie Vaccine (includes video) - www.kxmc.com - "There are researchers looking at a vaccine for prematurity. So now they are starting to work on those issues because a lot of women who go on to develop pre-term labor have an inflammatory process going on in their body and so there is a hope that some of these vaccines can prevent some of that." November 26, 2007 - FDA OK a shot in the arm for Akorn - Chicago Sun Times - "Buffalo Grove-based Akorn Inc. landed U.S. regulatory approval of a single-dose version of its tetanus diphtheria vaccine, the company said today. Shares of Akorn (AKRX) gained 14 cents, or 2 percent, to close at $7.01. It expects to launch the new vaccine the first quarter of next year." November 20, 2007 - New HPV vaccine 'nine-valent' under study - A new vaccine against nine of the most harmful strains of human papillomavirus is under study at the Medical College of Georgia. - www.news-medical.net September 2006 - Assembling a Global Vaccine Development Pipeline for Infectious Diseases in the Developing World - journal article (American Journal of Public Health) March 2006 - Vaccine pipeline looks bright for 2006 - New vaccines in the pipeline for HPV and other illnesses are keeping physicians on their toes. - Infectious Diseases in Children Red Book® - Online Table - NEW - Status of Licensure and Recommendations for New Vaccines* - AAP Red Book via American Academy of Pediatrics Vaccines in the Pipeline -- An Overview (December 2001) There are currently some 200 vaccines in the pipeline. Here is a list of some of them: ---------------------------------------------------------------------------------------------------------- New additions, recently compiled by Sheri Nakken, R.N., MA (added 9/7/02) adjusted search links12/3/07 Epstein Barr Vaccine http://www.google.com/search?hl=en&q=%22epstein+barr+vaccine%22&btnG=Search&meta= Cholesterol Vaccine http://www.google.com/search?hl=en&q=%22Cholesterol+vaccine%22&btnG=Google+Search&meta= Diabetes Vaccine http://www.google.com/search?hl=en&q=%22diabetes+vaccine%22&btnG=Google+Search&meta= Ulcer Vaccine http://www.google.com/search?hl=en&q=%22ulcer+vaccine%22&meta= Multiple Sclerosis Vaccine http://www.google.com/search?hl=en&q=%22multiple+sclerosis+vaccine%22&btnG=Search&meta= SV40 Vaccine - (for the SV40 you got from a vaccine) http://www.google.com/search?hl=en&q=%22sv40+vaccine%22&meta= Asthma Vaccine http://www.google.com/search?hl=en&q=%22asthma+vaccine%22&btnG=Search&meta= Arthritis Vaccine http://www.google.com/search?hl=en&q=%22arthritis+vaccine%22&btnG=Search&meta= Allergy Vaccine http://www.google.com/search?hl=en&q=%22allergy+vaccine%22&btnG=Search&meta= Strep Vaccine http://www.google.com/search?hl=en&q=%22strep+vaccine%22&btnG=Search&meta= Staph Vaccine http://www.google.com/search?hl=en&q=%22staph+vaccine%22&btnG=Search&meta= Clostridium Vaccine http://www.google.com/search?hl=en&q=%22Clostridium+vaccine%22&meta= Psoriasis Vaccine http://www.google.com/search?hl=en&q=%22psoriasis+vaccine%22&btnG=Search&meta= Nicotine Vaccine http://www.google.com/search?hl=en&q=%22nicotine+vaccine%22&btnG=Search&meta= Gonorrhea Vaccine http://www.google.com/search?hl=en&q=%22gonorrhea+vaccine%22&btnG=Search&meta= Syphilis Vaccine http://www.google.com/search?hl=en&q=%22syphilis+vaccine%22&btnG=Search&meta= Chlamydia Vaccine http://www.google.com/search?hl=en&q=%22chlamydia+vaccine%22&meta= Cocaine Vaccine http://www.google.com/search?hl=en&q=%22cocaine+vaccine%22&btnG=Search&meta= Anti-marijuana Vaccine http://www.google.com/search?hl=en&q=%22anti-marijuana+vaccine%22&meta= Lumpy Skin Disease Vaccine (yes you heard me right) http://www.google.com/search?hl=en&q=%22lumpy+skin+disease+vaccine%22&btnG=Search&meta= STD Vaccine http://www.google.com/search?hl=en&q=%22std+vaccine%22&meta= PCP vaccine http://www.behigh.org/library/press/other/california.html Osteoporosis Vaccine http://www.google.com/search?hl=en&q=%22osteoporosis+vaccine%22&meta= Parkinson's Vaccine http://www.google.com/search?hl=en&q=%22parkinson%27s+vaccine%22&meta= Anti-fertility vaccine http://www.google.com/search?hl=en&q=%22anti-fertility+vaccine%22&meta= Candida Vaccine http://www.google.com/search?hl=en&q=%22candida+vaccine%22&meta= http://www.ligocyte.com/article2.html Wart Vaccine http://www.google.com/search?hl=en&q=%22wart+vaccine%22&btnG=Search&meta= Herpes Vaccine http://www.google.com/search?hl=en&q=%22herpes+vaccine%22&meta= Periodontal Vaccine http://www.google.com/search?hl=en&q=%22periodontal+vaccine%22&meta= Dental Caries Vaccine http://www.google.com/search?hl=en&q=%22dental+caries+vaccine%22&meta= RSV Vaccine http://www.google.com/search?hl=en&q=%22rsv+vaccine%22&meta= Diarrhea Vaccine (not rotavirus) http://www.google.com/search?hl=en&q=%22diarrhea+vaccine%22&meta= Peanut Allergy Vaccine http://www.google.com/search?hl=en&q=%22peanut+vaccine%22&meta= Peanut Allergy http://www.sciencenews.org/sn_arc99/4_3_99/fob4ref.htm Childhood Diabetes www.medicalnewstoday.com/articles/17758.php Allergy http://www.google.com/search?hl=en&q=%22allergy+vaccine%22&meta= http://www.webmd.com:80/allergies/news/20071114/seasonal-allergy-vaccine-horizon CMV Vaccine http://www.google.com/search?hl=en&q=%22cmv+vaccine%22&meta= Fifth Disease Vaccine http://www.google.com/search?hl=en&q=%22fifth+disease+vaccine%22&meta= E Coli Vaccine http://www.google.com/search?hl=en&q=%22e-coli+vaccine%22&meta= Leptospirosis Vaccine http://www.google.com/search?hl=en&q=%22leptospirosis+vaccine%22&meta= Malaria Vaccine http://www.google.com/search?hl=en&q=%22malaria+vaccine%22&meta= Fungal Disease Vaccine http://www.google.com/search?hl=en&q=%22fungal+disease+vaccine%22&meta= Listeria Vaccine http://www.google.com/search?hl=en&q=%22listeria+vaccine%22&meta= Pseudomonas Vaccine http://www.google.com/search?hl=en&q=%22pseudomonas+vaccine%22&meta= Shigella Vaccine http://www.google.com/search?hl=en&q=%22shigella+vaccine%22&meta= Salmonella Vaccine http://www.google.com/search?hl=en&q=%22salmonella+vaccine%22&meta= Hay Fever Vaccine http://www.google.com/search?hl=en&q=%22hay+fever+vaccine%22&meta= Ragweed Vaccine http://www.google.com/search?hl=en&q=%22ragweed+vaccine%22&meta= Bladder Infection Vaccine http://www.google.com/search?hl=en&q=%22bladder+infection+vaccine%22&meta= Sinusitis Vaccine http://www.google.com/search?hl=en&q=%22sinusitis+vaccine%22&meta= Hookworm Vaccine http://www.google.com/search?hl=en&q=%22hookworm+vaccine%22&meta= Schistosomiasis Vaccine http://www.google.com/search?hl=en&q=%22schistosomiasis+vaccine%22&btnG=Search&meta= Typhoid Vaccine for Children http://www.google.com/search?hl=en&q=%22typhoid+vaccine%22+children&btnG=Search&meta= Spinal Cord Injury Vaccine http://www.google.com/search?hl=en&q=%22spinal+cord+injury+vaccine%22&meta= Hepatitis E Vaccine http://www.google.com/search?hl=en&q=%22hepatitis+e+vaccine%22&meta= Hepatitis C Vaccine http://www.google.com/search?hl=en&q=%22hepatitis+c+vaccine%22&meta= Alzheimer's Vaccine http://www.google.com/search?hl=en&q=%22alzheimer%27s+vaccine%22&meta= Hope For Alzheimer's Vaccine - Disease Could Affect 14 Million Americans By 2050 - CBS http://www.cbsnews.com/stories/2000/07/08/tech/main213485.shtml Ebola Vaccine http://www.google.com/search?hl=en&q=%22ebola+vaccine%22&meta= Vaccine for Penicillin-Resistant Infection http://www.google.com/search?hl=en&q=%22Penicillin+Resistant+vaccine%22&meta= Cancer http://www.google.com/search?hl=en&q=%22cancer+vaccine%22&meta= Genital Herpes http://www.google.com/search?hl=en&q=%22genital+herpes+vaccine%22&meta= New TB http://www.google.com/search?hl=en&q=%22tb+vaccine%22&meta= Genetic http://www.google.com/search?hl=en&q=%22genetic+vaccine%22&meta= Rheumatoid Arthritis http://www.google.com/search?hl=en&q=%22rheumatoid+arthritis+vaccine%22&meta= H Pylori http://www.google.com/search?hl=en&q=%22h+pylori+vaccine%22&meta= Cat Allergy http://www.google.com/search?hl=en&q=%22cat+allergy+vaccine%22&meta= Ringworm http://www.google.com/search?hl=en&q=%22ringworm+vaccine%22&btnG=Search&meta= Gonorrhea http://www.google.com/search?hl=en&q=%22gonorrhea+vaccine%22&meta= C.difficile http://www.google.ca/search?hl=en&q=%22c-difficile+vaccine%22&meta= MRSA www.medicalnewstoday.com/articles/55484.php Hypertension http://www.google.com/search?hl=en&q=%22hypertension+vaccine%22&btnG=Search&meta= Brain Cancer http://www.google.com/search?hl=en&q=%22brain+cancer+vaccine%22&meta= Vaccines in the Pipeline - also see Pipeline in recommended list
|
 "A foolish faith in authority is the worst enemy of truth." -- Albert Einstein, letter to a friend, 1901 "I know of no safe depository of the ultimate powers of the society but the people themselves, and if we think them not enlightened enough to exercise control with a wholesome discretion, the remedy is not to take it from them, but to inform their discretion by education." -- Thomas Jefferson, letter to William C. Jarvis, September 28, 1820  Free Shipping Everyday - Visit babyearth.com today for innovative products and free shipping with minimum purchase.                     BabyandMeBoutique.com -Now offering free shipping on all orders! Unique gifts, high quality producs for baby and mom including baby furniture, baby strollers, baby toys, maternity gear, hip diaper bags and more.            Free Shipping at EarthTech on Orders of 150 and up! SHOP NOW         Patented personal and medical ID bracelets. Great for kids & travel, runners & cyclists, seniors, and medical alert.                 |
